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Abstract Multidrug resistance-associated protein (MRP), a 
member of the ABC superfamily transporters, functions as an 
ATP-dependent efflux pump that extrudes cytotoxic drugs from 
the cells. Although glutathione has been considered to play an 
important role in the function of MRP, there is no convincing 
evidence that glutathione directly interacts with MRP. Here we 
demonstrate that vanadate-induced trapping of 8-azido-ATP in 
MRP was stimulated in the presence of glutathione, oxidized 
glutathione and the anti-cancer drugs VP-16 and vincristine. 
MRP in membrane from a human MRP cDNA transformant 
was specifically photolabeled with 8-azido-[a-32P]ATP by the 
vañádate-trapping technique. Vanadate and Mg2+ were required 
for trapping of nucleotides, and vanadate trapping of nucleotides 
was inhibited by excess ADP as well as ATP. These results 
suggest that a stable inhibitory complex MRP-MgADP-Vi, an 
analog of the MRP-MgADP-Pi transition state complex, is 
formed in the presence of vanadate. Glutathione as well as anti-
cancer drugs would directly interact with MRP, and stimulate 
the formation of the transition state of the ATPase reaction of 
MRP. 
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1. Introduction 
Multidrug resistance (MDR) of tumor cells is a major ob-
stacle in cancer chemotherapy. This phenomenon is frequently 
associated with the expression of P-glycoprotein (Pgp) and 
multidrug resistance-associated protein (MRP), both members 
of the ABC superfamily of transporters [1]. Pgp and MRP 
function as ATP-dependent efflux pumps that extrude cyto-
toxic drugs from the cells before the drugs reach their intra-
cellular targets, thus conferring resistance to many structurally 
dissimilar anti-cancer drugs, such as the Vinca alkaloids, col-
chicine, actinomycin D, epipodophyllotoxins, taxol, and an-
thracyclines [2-6]. However, the mechanism of transport for 
MRP could be different from that for Pgp, because the deple-
tion of intracellular glutathione by buthionine sulfoximine 
(BSO) results in a complete reversal of resistance to anti-can-
cer drugs of some cell lines expressing MRP [7,8], but BSO 
has no effect on Pgp-mediated MDR. 
It has been reported that MRP transports leukotriene C4, a 
glutathione conjugate, and that MRP mediates ATP-depend-
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ent transport of vincristine in the presence of glutathione [9-
12]. These results suggest that glutathione is important in the 
function of MRP. However, the mechanism by which glu-
tathione helps in vitro ATP-dependent vincristine transport 
and in vivo efflux of anti-cancer drugs from cells by MRP is 
unclear. There is no convincing evidence that glutathione di-
rectly interacts with MRP. 
MRP-mediated transport is ATP-dependent, and non-hy-
drolyzable ATP analogs cannot support MRP-mediated 
transport [9-12]. The mechanism of ATP hydrolysis by Pgp 
has been studied [13-15] and it was recently reported that the 
apparent affinity for nucleotides of Pgp was greatly increased 
in the presence of vanadate [16,17], probably because a stable 
and reversible inhibitory complex was generated by trapping 
nucleotide at the catalytic site. Although MRP and Pgp share 
only 15% amino acid identity, the 'ATP binding cassette' re-
gions of these proteins are highly homologous [18]. We there-
fore expected that the mechanism of ATP hydrolysis by MRP 
could be analogous to that by Pgp, and that vanadate trap-
ping with 8-azido-ATP followed by UV irradiation might 
cause specific labeling of MRP as in the case of Pgp. 
2. Materials and methods 
2.1. Materials 
The monoclonal antibody C219 was purchased from Centocor, and 
QCRL-1 [19] was provided by Dr. S. Cole, Queen's University, King-
ston, Ont, Canada. Human MRP expression vector pJ3Q-MRP [4] 
was provided by Dr. G.J.R. Zaman, Netherlands Cancer Institute. 
Vinblastine, colchicine, actinomycin D, taxol, and doxorubicin were 
purchased from Wako Pure Chemical Industries. VP-16 was from 
Sigma. 8-Azido-[a-32P]ATP was purchased from ICN Biomedicals. 
2.2. Transfection and drug resistance assay 
Human cultured KB-3-1 cells were propagated in Dulbecco's mod-
ified Eagle's medium with 10% fetal bovine serum under 5% CO2 at 
37°C. KB-3-1 was cotransfected with pJ3£2-MRP and pSV2neo with 
LipofectAMINE (Gibco) according to the manufacturer's directions. 
Cells were first selected in the presence of 0.8 mg/ml gentamicin 
(G418) for 10 days. The mass populations of gentamicin-resistant 
colonies were further selected in stepwise increasing concentrations 
(5, 20, 40 ng/ml) of doxorubicin. KB-3-1 cells transfected with 
pSV2neo formed no colonies in media containing 5 ng/ml of doxo-
rubicin. The IC50 (the drug concentration that inhibits cell growth by 
50%) was measured by a colorimetric assay using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from dose-response 
curves for increasing concentrations of vinblastine, colchicine, actino-
mycin D, taxol, doxorubicin, and VP-16. 
2.3. Vanadate trapping of 8-azido-ATP and subsequent photoaffinity 
labeling of MRP 
Membrane proteins (20 |xg) were incubated with 200 |xM vanadate, 
3 mM MgS04, 2 mM ouabine, 0.1 mM EGTA, 20 irM 8-azido-
[a-32P]ATP, and 40 mM Tris-HCl (pH 7.5), in a total volume of 20 
|xl for 10 min at 37°C. (Variations of these conditions are described in 
the figure legends.) The reactions were stopped by addition of 400 ul 
of ice-cold Tris-EGTA buffer (0.1 mM EGTA, 40 mM Tris-HCl (pH 
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7.5)), and free ATP, Mg2+, and vanadate were removed after centri-
fugation (15000Xg, 10 min, 4°C). The pellet was washed in the same 
buffer and was resuspended in 8 (il of Tris-EGTA buffer, placed on 
ice, and irradiated for 5 min (k = 254 nm, 5.5 mW/cm2). Samples were 
electrophoresed on SDS-polyacrylamide gel, then autoradiographed. 
The amount of trapped 8-azido-[rx-32P]ATP in MRP was measured by 
counting the radioactivity of the band of MRP excised from a SDS 
gel. Experiments were done in duplicate or triplicate. 
3. Results 
A stable transformant, KB/MRP, was made by introducing 
an expression vector, pJ3C2-MRP, containing the human 
MRP cDNA into a drug-sensitive human carcinoma cell 
line, KB-3-1. MRP was detected as a 190-kDa protein with 
the MRP-specific monoclonal antibody QCRL-1 in KB/MRP 
membrane, but not in KB/MDRl membrane (Fig. 1A). Pgp 
was not detected in KB/MRP membrane (Fig. IB). Pgp or 
MRP was not detected in the parental KB-3-1 membrane. 
The spectrum of multidrug resistance of KB/MRP cells was 
similar to that of KB/MDRl (Fig. 1C): they were resistant 
to doxorubicin, VP-16, vinblastine, colchicine, actinomycin 
D, and taxol. But patterns of drug resistance were quite char-
acteristic: KB/MRP cells were preferentially resistant to 
VP-16 and KB/MDRl cells to taxol as reported previously 
[3,4]. 
Pgp has been reported to have a drug-stimulated ATPase 
activity [13], and hence drug transport and ATP hydrolysis 
are considered to be coupled directly. In the presence of va-
nadate, Pgp forms a stable and reversible inhibitory complex 
with MgADP-Vi after ATP hydrolysis [16,17]. Because MRP-
mediated transport requires ATP and non-hydrolyzable ATP 
analogs cannot support it [9-12], MRP-mediated transport is 
also considered to be coupled to ATP hydrolysis. The vana-
date trapping technique was so effective for investigating cat-
alytic sites of Pgp that we first examined if vanadate induces 
trapping of nucleotides in MRP as it does in Pgp. 
When membrane proteins from KB/MRP cells were incu-
bated with vanadate, Mg2+, and 8-azido-[a-32P]ATP, followed 
by UV irradiation, a 190-kDa protein was specifically photo-
affinity-labeled (Fig. 2, lane A4). No specific photoaffinity-
labeled protein was observed in membrane proteins from 
KB-3-1 (lane Al), and the mobility in SDS-PAGE of the 
photoaffinity-labeled protein in KB/MRP membrane was 
identical to that of MRP in the Western blot (data not 
shown), indicating that MRP in KB/MRP membrane was 
photolabeled with 8-azido-[oc-32P]ATP in the presence of va-
nadate. Both vanadate and Mg2+ were required for the photo-
affinity labeling (lanes A2 and A3). Vanadate trapping was 
inhibited by an excess of ATP (lane A5) or ADP (lane A6). 
These results suggest that the apparent affinity for ATP of 
MRP was quite low and was greatly increased in the presence 
of vanadate. 
We examined the effect of substrates for MRP on vanadate 
trapping. Vanadate trapping of nucleotides was increased 
about 3-fold by VP-16 (Fig. 2, lanes B4 and D4) and vincris-
tine (lane C3), 1.5-fold by doxorubicin (lanes B6 and D6), and 
1.2-1.3-fold by verapamil (lanes B2 and D2), vinblastine 
(lanes B3 and D3), and taxol (lanes B5 and D5). These results 
corresponded to the resistance spectrum of MRP-overexpres-
sing cells including KB/MRP in this report: preferential resist-
ance to VP-16 and vincristine, moderate resistance to doxo-
rubicin, and low resistance to taxol and vinblastine. These 
results suggested that VP-16 and vincristine interacted with 
MRP directly in the absence of glutathione, although trans-
port of these drugs by MRP was reported to be dependent on 
intracellular glutathione [7,8]. 
Then we examined the effect of glutathione on vanadate 
trapping of nucleotides in MRP, and found that 20 ^M glu-
tathione (Fig. 2, lanes B7, C2, and D7) and oxidized glu-
tathione (lanes B8 and D8) increased vanadate trapping of 
nucleotides about 3-fold. These results suggest that glu-
tathione interacts with MRP directly. Vanadate trapping of 
nucleotides was further stimulated by 1 mM and 3 mM glu-
tathione (lanes C4 and C6). The effect of 3 mM glutathione 
was weaker than that of 1 mM glutathione, suggesting that 
the physiological concentration of glutathione may have a 
maximal stimulatory effect on the ATPase activity of MRP. 
Interestingly, the effects of 1 mM (lane C5) and 3 mM glu-
tathione (lane C7) on vanadate trapping were rather depressed 
in the presence of 20 |J,M vincristine. 
Fig. 1. Immunoblot analysis of MRP and Pgp in membrane protein fractions of KB/MRP, KB/MDRl, and untransfected KB-3-1 cells with 
the anti-MRP monoclonal antibody QCRL-1 (A) or with the anti-Pgp monoclonal antibody C219 (B). Lane 1, KB/MRP; lane 2, KB/MDRl; 
lane 3, KB-3-1. Membrane proteins (20 itg) were separated in a 7% SDS-polyacrylamide gel. Molecular size standards are indicated in kDa on 
the left. C: Relative resistance of KB/MRP (black bars) and KB/MDRl cells (hatched bars). Relative resistance was calculated by dividing the 
IC50 values (concentration required for inhibiting growth rate by 50%) against each drug by those of KB-3-1 cells. Each bar represents the 
average of three experiments. 
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Fig. 2. Stimulation of vanadate-induced trapping of nucleotide in MRP by anti-cancer drugs and glutathione. A: Photoafflnity labeling of 
MRP in plasma membrane with 8-azido-ATP in the presence of Mg2+ and vanadate. Plasma membrane proteins (20 ug) from KB-3-1 (lane 1) 
or from KB/MRP (lanes 2-6) were reacted with 20 uM 8-azido-[a-32P]ATP, 200 |xM vanadate, and 3 mM MgS04, and analyzed as described 
in Section 2. Incubations were done in the absence of vanadate (lane 2) or MgS04 (lane 3), or in the presence of 2.5 mM ATP (lane 5), or 
ADP (lane 6). Experiments were done three times independently. B: Stimulation of vanadate-induced trapping by anti-cancer drugs and glu-
tathione. Plasma membrane proteins (20 ug) from KB/MRP were reacted with 20 uM 8-azido-[a-32P]ATP, 200 uM vanadate, and 3 mM 
MgS04 in the presence of 20 |xM verapamil (lane 2), vinblastine (lane 3), VP-16 (lane 4), taxol (lane 5), doxorubicin (lane 6), glutathione (lane 
7), or oxidized glutathione (lane 8). Experiments were done three times independently. C: Plasma membrane proteins (20 ug) from KB/MRP 
were reacted with 20 uM 8-azido-[a-32P]ATP, 200 uM vanadate, and 3 mM MgS04 in the presence of 20 uM glutathione (lane 2), or vincris-
tine (lane 3), 1 mM glutathione (lane 4), 1 mM glutathione and 20 uM vincristine (lane 5), 3 mM glutathione (lane 6), 3 mM glutathione and 
20 uM vincristine (lane 7). Experiments were done twice independently. D: Relative stimulation of vanadate trapping of nucleotides in MRP. 
The amount of trapped 8-azido-[a-32P]ATP in MRP was measured by counting the radioactivity of the band of MRP excised from a SDS gel 
shown in B. Relative stimulation was calculated by dividing the amount of trapped nucleotide by that of lane Bl. Each bar represents the aver-
age of three independent experiments. 
4. Discussion 
We showed that MRP in KB/MRP membrane could be 
specifically photolabeled with 8-azido-[cc-32P]ATP by the va-
nadate trapping technique. Vanadate and Mg2+ were required 
for trapping of nucleotides, and vanadate trapping of nucleo-
tides was inhibited by excess ADP as well as ATP. Vanadate-
induced trapping of nucleotides at the catalytic site was ex-
tensively studied with myosin [20,21] and Pgp [16,17], and in 
both cases vanadate was accepted as an analog of inorganic 
phosphate and a stable and reversible inhibitory complex was 
generated by trapping MgADP-Vi at the catalytic site. These 
results suggest that MRP, like Pgp, has no high-affinity bind-
ing site for MgATP, but forms a metastable state (E-MgADP-
Pi, where E is MRP or Pgp) after hydrolysis, and the phos-
phate ion is released before MgADP. A minimal reaction 
k+i k+? 
Pi 
k+3 k+4 
MRP + MgATP5=* MRP' MgATP5=*MRP'MgADP- Pi s=* MRP-MgADPi=* MRP + MgADP 
k-l k-2 k-3 k-4 
V^k+Sjfk, 
MRP-MgADP'Vi 
Scheme 1. 
pathway for vanadate-induced trapping of nucleotides in 
MRP could be speculated to be like Scheme 1. The first cat-
alytic turnover in MRP produces an intermediate containing 
ADP, and then vanadate binds to this intermediate to form a 
stable inhibitory complex, MRP-MgADP-Vi. MgADP could 
also be trapped at the catalytic site by pathway k_4, and 
this would be why excess ADP inhibited vanadate-induced 
trapping of nucleotide. This inhibitory complex would be an 
analog of the MRP-MgADP-Pi transition state complex. 
Cell lines overexpressing MRP are resistant to VP-16, vin-
cristine, and doxorubicin, and these drugs were reported to be 
substrates for MRP to transport [3,4]. On the other hand, cell 
lines overexpressing MRP showed only low resistance to vin-
blastine and taxol. Verapamil has only a weak effect on drug 
resistance of KB/MRP cells (data not shown). Vanadate trap-
ping of nucleotides was increased about 3-fold by VP-16 and 
vincristine, and weakly or marginally by doxorubicin, vinblas-
tine, taxol, and verapamil. These results indicate that prefer-
ential substrates for MRP to transport stimulate vanadate-
induced trapping of nucleotide in MRP, i.e. the formation 
of the transition state of the ATPase reaction of MRP. 
Glutathione has been considered to be important in the 
function of MRP, but there was no convincing evidence 
that GSH directly interacts with MRP. In this work, we 
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demonstrated that glutathione strongly stimulated vanadate-
induced trapping of nucleotides in MRP, suggesting that glu-
tathione as well as anti-cancer drugs would directly interact 
with MRP. It is assumed that MRP contains a bipartite bind-
ing site for hydrophobic moieties of substrates and glu-
tathione that would allow binding of covalent or non-covalent 
drug-glutathione complexes, or the sequential binding of glu-
tathione and drug [12]. The depressing effects of 20 |J,M vin-
cristine on vanadate trapping induced by 1 m M and 3 m M 
glutathione (Fig. 2) may suggest that binding sites for anti-
cancer drugs and glutathione are not independent but overlap 
or closely interact with each other. 
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